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ABSTRACT
SENSITIVE AND SPECIFIC DETECTION OF SARS-COV-2 IN SALIVA USING REVERSE
TRANSCRIPTASE LOOP-MEDIATED ISOTHERMAL AMPLIFICATION

By
Casey Leigh Juntila
A novel coronavirus called SARS-CoV-2 has caused the emergency release of the most
well-known molecular assay, the CDC N1 RT-PCR assay, causing reports of poor analytical
performance resulting in false-negative results (20, 26), and inconsistent testing kits received
(23, 32). An immediate and dire need for a rapid and reliable SARS-CoV-2 testing workflow
specifically designed for a university setting is the purpose this project is aiming and intended to
fulfill. The workflow design uses a less invasive saliva sample for rapid screening using
colorimetric RT-LAMP detection of three SARS-CoV-2 gene regions for Orf1ab, envelope, and
nucleocapsid. Purified SARS-CoV-2 genomic RNA is spiked into Proteinase K and heat-treated
saliva from a SARS-CoV-2 negative donor to simulate a positive donor sample used to
characterize and optimize this workflow, detecting 200 copies of SARS-CoV-2 genomic RNA
by all three gene targets. The utility of colorimetric RT-LAMP outperformed the CDC N1 RTPCR assay in turn-around-time and analytical performance. When applied to a small surveillance
study, five out of 47 asymptomatic saliva donors had (September 2020) detectable SARS-CoV-2
genetic material, resulting in a 10% positivity rate, with the campus dashboard reporting <1%.
With a higher SARS-CoV-2 prevalence rate detectable through this workflow than what the
university was previously finding using the suboptimal RT-PCR testing, the surveillance shut
down due to lack of confirmatory testing supplies.
i

Copyright by
Casey Leigh Juntila
2021
ii

TABLE OF CONTENTS

List of Tables…………………………………………………...…………………………....……v
List of Figures…………………………………………………………………….………..…vi-vii
Introduction and Literature Review……………………….….………………....………………1-9
Methods……………………………………………………………..…………………………9-17
Real-Time Polymerase Chain Reaction…………………………..……………………9-10
CDC N1 RT-PCR Assay Design …………………….………..………………9-10
Reverse-Transcriptase Loop-Mediated Isothermal Amplification……………...……10-14
RT-LAMP Assay Design…………………….……………………….………10-12
RT-LAMP Colorimetric End-Point Analysis…………...…………...……...…...13
RT-LAMP Turbidimetric End-Point Analysis……………….………………13-14
Enzyme Restriction Digest……………….………………..…………………………14-16
Restriction Digest Design………….…….…………………………………...14-15
Agarose Gel Electrophoresis………………………...……………………….15-16
Samples…………………………………………….…………………………..……..16-17
Donor Sample Collection…………………………………………………….…..16
Saliva Treatment…………………………………………………………………16
Contrived samples………………………………………..………………………17
Results………………………………………………………………………………….….…17-40
CDC N1 RT-PCR Results…………………………………...………………….…....17-23
RT-LAMP Colorimetric Results………………………………………......................23-27
Restriction Digest Results………………………………………...………….………28-34
Purified SARS-CoV-2 Genomic RNA………………………………….……28-31
Contrived Samples…………………………………………………….…..….31-34
RT-LAMP Turbidimetric Results…………………………………………………….35-37

iii

Surveillance Study……………………………………………………………………37-40
Discussion…………………………………………………………………………….………41-47
References……………………………………………………………………………………48-51
Appendix A……………………………………………………………………………….…..…52

iv

LIST OF TABLES
Table 1 LAMP Complete Primer Mix Specifications…………………………………………....11
Table 2 RT-LAMP Primer Sequences for Orf1ab, Envelope, and Nucleocapsid…………....….12
Table 3 Colorimetric RT-LAMP Complete Master Mix Components…………………………..13
Table 4 Turbidimetric RT-LAMP Complete Master Mix Components……………………..…..14
Table 5 Restriction Digest Reaction Components………………………………………...……..15
Table 6 RT-PCR Data of Amplified SARS-CoV-2 Genomic RNA………………………….….28
Table 7 RT-PCR Data of Amplified SARS-CoV-2 in Contrived Samples……………...………32

v

LIST OF FIGURES
Figure 1 SARS-CoV-2 Virion, and Genome Organization……………………………………….3
Figure 2 LAMP Primer Binding Schematics……………………………………………………...8
Figure 3 CDC N1 Primer and Probe Alignment to SARS-CoV-2 Nucleocapsid Genomic
Sequence…………………………………………………………………………………………10
Figure 4 Orf1ab Primer Alignment to SARS-CoV-2 Genomic Sequence………………………11
Figure 5 Envelope Primer Alignment to SARS-CoV-2 Genomic Sequence……………….……11
Figure 6 Nucleocapsid Primer Alignment to SARS-CoV-2 Genomic Sequence……………..…12
Figure 7 Restriction Digest Design……………………………………………………………....15
Figure 8 Non-specific Binding of CDC N1 RT-PCR Forward and Reverse Primer Using SYBR
Green 1…………………………………………………………………………………………...18
Figure 9 Poor Test Performance of CDC N1 RT-PCR Using CDC Recommended N1 Primer and
Probe Concentrations………………………………………………………………………….....19
Figure 10 Failed Optimization for CDC N1 RT-PCR Primer and Probe Concentrations…….…20
Figure 11 Failed Optimization of CDC N1 RT-PCR Primer and Probe Annealing
Temperatures……………………………………………………………………………………..21
Figure 12 Failed Optimization of CDC N1 RT-PCR With Enhancer Reagent………………….23
Figure 13 Colorimetric RT-LAMP of SARS-CoV-2 gRNA Limit of Detection…………….….24
Figure 14 Colorimetric RT-LAMP of SARS-CoV-2 gRNA Limit of Detection Confirmation....25
Figure 15 Colorimetric RT-LAMP of SARS-CoV-2 Contrived Samples Limit of Detection…..26
Figure 16 Colorimetric RT-LAMP of SARS-CoV-2 Contrived Samples Limit of Detection
confirmation……………………………………………………………………………………...27
Figure 17 RT-PCR Analysis of SARS-CoV-2 Genomic RNA……………………………….…29
Figure 18 Restriction Digest Confirms Amplification of SARS-CoV-2 Purified Genomic
RNA……………………………………………………………………………………………...30
Figure 19 RT-PCR Analysis of Amplified SARS-CoV-2 Nucleic Acid from Contrived
Samples…………………………………………………………………………………………..32
Figure 20 Restriction Digest of Amplified SARS-CoV-2 Nucleic Acid from Contrived
Samples…………………………………………………………………………………………..33
Figure 21 Turbidimetric LAMP Detection of SARS-CoV-2 in Contrived Samples…………….35
vi

Figure 22 Turbidimetric RT-LAMP Detection of SARS-CoV-2 in Contrived Samples
Confirmation……………………………………………………………………………………..36
Figure 23 Donor Saliva Samples 001-027 Tested Using Colorimetric RT-LAMP for SARS-CoV2 Nucleocapsid Gene…………………………………………………………………………….38
Figure 24 Donor Saliva Samples 028-035 Tested using Colorimetric RT-LAMP for SARS-CoV2 Orf1ab, Envelope, and Nucleocapsid Genes…………………………………………………...39
Figure 25 Donor Saliva Samples 036-047 Tested using Colorimetric RT-LAMP for SARS-CoV2 Orf1ab, Envelope, and Nucleocapsid Genes…………………………………………………...40

vii

INTRODUCTION AND LITERATURE REVIEW

This Thesis follows the format specified by the 7th Edition of the Publication manual of
the American Psychological Association. Severe Acute Respiratory Syndrome Coronavirus 2,
SARS-CoV-2, and COVID-19 are all used to describe a novel virus discovered in late 2019 in
Wuhan, China, that has been responsible for the continued accumulation of more than 3 million
deaths worldwide (29). The origins of this virus speculated to begin in bat or pangolin species,
subsequently acquiring mutations or undergoing recombination events allowing for zoonotic
transmission to humans (2). These have been the suggested models due to high sequence
homology between the S gene of SARS-CoV-2 and the genes of coronaviruses specifically found
in bat or pangolin hosts (2).
COVID-19 disease harbors many symptoms in an infected person or can cause an
asymptomatic carrier-like infection (6). Symptoms can include but are not limited to fever, chills,
cough, fatigue, or a characteristic loss of taste and smell, with symptom onset occurring 2-14
days after initial infection (6). In severe cases, acute respiratory distress syndrome can develop,
more commonly known as a cytokine storm, a highly erratic inflammatory response that can be
lethal (22). Transmission of infection is through respiratory droplets created from an infected
individual when sneezing, speaking, or coughing (5). The high-risk mortality group for this
infection is anyone ≥60 years of age and anyone with underlying health conditions (5).
SARS-CoV-2 is a spherical enveloped virus roughly 120 nm in diameter containing a
positive-sense single-stranded RNA genome with an approximate size of 30,000 bases (15). The
genomes' basic structure begins with a 5' CAP and 3' Poly-A-tail and is bound to nucleocapsid
structural proteins producing a helical conformation (15). This virus belongs to
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the Coronaviridae family and Betacoronavirus genus of viruses (9, 19). The genome size of
viruses within this group includes giant viral RNA genomes cataloged to this date (9).
The Betacoronavirus genus is genetically distinguished from the Alpha, Gamma, and Delta
groups by a specific non-structural proteins’ gene size and sequence variation. In addition, Alpha
and Betacoronaviruses infect mammalian hosts, Gammacoronaviruses infected avian hosts,
and Deltacoronaviruses can infect both mammalian and avian hosts (9). Of the many different
coronavirus species, the four common coronavirus species that infect human hosts are Human
Coronavirus 229E, NL63, OC43E, and HKU1 (1).
Once a SARS-CoV-2 viral particle is endocytosed, within a host cell, viral replication
occurs through discontinuous transcription of 13-15 open reading frames, of which 12 are
functional, resulting in the production of four structural proteins and 16 non-structural proteins
(18). The four structural proteins include the spike protein, which mediates viral entry into host
cells through spike protein and host angiotensin-converting enzyme 2, or ACE2, cell-surface
receptor interaction (9, 21). Structural proteins are involved in new virion formation, virion
release, host cell entry, and other vital functions in the viral lifecycle (21). The 16 non-structural
proteins perform various roles involved in viral replication, survival, and host immune system
evasion (18). In figure 1 below is a depiction of a cartoon image of a SARS-CoV-2 virion
highlighting the four structural proteins nucleocapsid (b), spike (c), envelope (d), membrane (e),
and the genomic RNA (a), along with the organization of the RNA genome.
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A

B

Figure 1 SARS-CoV-2 Virion, and Genome Organization. (A) SARS-CoV-2 structural proteins
nucleocapsid (b), spike (c), envelope (d) and membrane (e) are identified along with the helical genomic
RNA (a). (B) Genomic organization of identified SARS-CoV-2 genes with structural proteins in light
gray.

Asymptomatic carrier infections of COVID-19 disease bring a unique challenge to
restricting viral spread throughout the community, as testing resources are being reserved for
symptomatic cases in addition to individuals not knowing they are sick. Those asymptomatic
carriers are likely not taking the appropriate quarantine measures and are unknowingly
promoting community spread of the virus. Attention to these two factors is the key to developing
a better strategy for managing this pandemic, as there would be a plan in place for symptomatic
and asymptomatic infection transmission.
December 31st, 2019, was the initial report of the first group of COVID19 cases in
China, and March 11th, 2020, officially declared a pandemic by the World Health Organization
(WHO) (28). The action taken by the FDA in response to the emerging global public health risk
was the emergency release of a CDC developed Real-time Polymerase Chain Reaction (RTPCR) SARS-CoV-2 assay in February of 2020 for the use in diagnosis and monitoring relying on
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the detection of the SARS-CoV-2 nucleocapsid gene (16). In response to the ongoing pandemic,
the FDA authorized the emergency release of the CDC developed RT-PCR assay, which
provided a much-needed test for the diagnosis and monitoring of the novel SARS-CoV-2 virus.
Despite the positive impact of the development of the test, its emergency release left potentially
unresolved shortcomings of the analysis. Resolution of shortcomings occurs during a standard
and necessary validation process required for all high-complexity testing that the FDA
investigates to prevent inaccuracies in reporting.
Real Time-Polymerase Chain Reaction (RT-PCR) utilizes the basic PCR principle in
addition to real-time monitoring of amplification. Polymerase Chain Reaction, or PCR, utilizes
three main stages in its methodology, denaturation, annealing, and extension (3). The first step of
denaturation occurs at approximately 95°C breaking the hydrogen bonds between doublestranded DNA, resulting in single strands. The second step of annealing is temperaturedependent based on primer composition though generally occurring from 55-65°C. PCR uses
primers are specially designed short oligonucleotide sequences 20-30 base pairs in length that
bind to their desired region using Watson-Crick base pairing rules and provide a starting point
for replication. The extension is the last stage of PCR occurring at 72°C allowing the Thermus
aquaticus (Taq) DNA polymerase to extend off the primer's 3' end, creating a complimentary
copy of the target. Taq polymerase creates phosphodiester bonds between two nucleotides by
joining a 3' hydroxyl group of one nucleotide to a 5' phosphate group of another nucleotide base
(3).
This three-step process of denaturation, annealing, and extension occurs multiple times,
commonly referred to as cycles (3). The real-time characteristic of RT-PCR is possible by
utilizing signaling molecules or dyes, allowing for fluorescent detection to generate a graph
4

displaying the level of fluorescent intensity as the reaction occurs (3). Two critical pieces of
information gathered from an RT-PCR amplification curve are the efficiency of the reaction and
the Ct-value. Reaction efficiency is determined by the visual shape of the amplification curve,
with a sigmoidal shape indicating optimal efficiency. The Ct-value is used to quantify genetic
material within a sample, in which the Ct-value is the cycle at which the fluorescence crosses the
threshold or base level of the fluorescent signal (24).
Taqman probes are a common component used in RT-PCR molecular assays, which
allow for fluorescent detection and enhance analytical specificity as this probe binds to its
specific target region. A Taqman probe consists of a recognition sequence, a 3' quencher, and a 5'
fluorophore. The fluorophore's fluorescence is quenched or absorbed by the quencher until it is
cleaved off by the Taq polymerase enzyme during the extension step of the PCR cycle. This
cleaving occurs after the probe binds to its complementary sequence, and the polymerase enzyme
replicates through the probe using the 5’3' exonuclease activity, releasing the fluorophore
allowing enough distance from the quencher signal to be detected (3).
A nucleic acid dye commonly used in RT-PCR is SYBR Green 1, which binds nonspecifically to any double-stranded DNA molecule (3). During the extension step of PCR
reaction, as polymerase creates the complementary sequence to the target sequence, SYBR
Green 1 will bind to the double-strand as produced. The more double-stranded target generated,
the more SYBR Green 1 will bind, and the more fluorescent signal will be generated (3).
A post-amplification analysis in RT-PCR called a melt curve analysis utilizes SYBR
Green 1 fluorescence for sequence identification (3). After all PCR cycles, the reactions are
slowly heated to 95°C causing the denaturation or separation of double-stranded sequences. As
the denaturation of sequences occurs, SYBR Green 1 will dissociate, and the fluorescent signal
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will decrease. A sequence's melt temperature is when half of the target sequence becomes singlestranded, which depends on the sequence composition. Cytosine and Guanine base pairs require
more heat (energy) to separate than Adenine and Thymine due to more hydrogen bonds holding
them together. This analysis generates curves or peaks from which an RT-PCR reaction
specificity or use for sequence identity can be performed (3).
A restriction digest is another laboratory technique used to aid in nucleic acid sequence
identification using restriction enzymes that recognize a specific sequence and ‘cut’ the DNA
backbone in a single strand or both strands at a specific site. The desired sample type for a
restriction digest is a purified nucleic acid sample with a known sequence composition
commonly produced using PCR. Using the SARS-CoV-2 nucleic acid sequence for analysis and
the many available computer programs can determine which restriction enzymes will cut a
sequence, how many cut sites are present. Once selected, the enzyme and nucleic acid sequence
will be incubated at the appropriate temperature for digestion to occur, followed by inactivation
of the enzyme if necessary. After a sequence has digestion, post-analysis of fragments using gel
electrophoresis allows for sequence separation and identification based on length.
The scientific community’s response to the emergency released CDC N1 assay generated
reports of false-negative results from the suboptimal assays (20, 26) and variances found
between testing kits (23, 32). These unoptimized tests have led to an increase in inaccurate
results due to this emergency release and the requirement of additional work for laboratories
performing these tests to optimize and resolve test shortcomings, which is yet another burden for
already strained laboratory personnel. Novel virus detection can potentially create other
shortcomings because of the lack of understanding of the virus and infection scientifically. As is
the case with SARS-CoV-2, with studies reporting assay dependency on viral load development,
6

ultimately plays a role in discrepant and false-negative results (12, 14). These inaccuracies
indicate an optimal testing window in which a certain amount of time must pass after initial
infection, such that enough viral replication has occurred to be detectable using the desired
testing methodology or specimen type.
Among the many molecular techniques used in diagnostics, LAMP and RT-LAMP
applications are prevalent in many different clinical research areas such as microbiology and
oncology due to the desirable attributes previously mentioned. In the context of SARS-CoV-2
application, LAMP primers have been previously designed and tested for targeting the
nucleocapsid (31), envelope (30), and Orf1ab (13) genes generating comparable results to the
designated gold standard, RT-PCR, increasing the potential of its application in COVID19
diagnosis. In addition, studies have shown that in place of the traditional nasopharyngeal swab
sample type, saliva is a promising sample alternative (8, 10, 11, 17), and evidence of a simple
pre-treatment increases detection efficiency (17, 25).
Loop-Mediated Isothermal Amplification (LAMP) is an isothermal strand displacement
nucleic acid amplification methodology recently developed by Notomi et al. (19). In contrast to
many other traditional amplification methods, LAMP amplifies a target sequence at a constant
temperature of approximately 65°C. LAMP employs a Bacillus stearothermophilus (Bst) DNA
polymerase enzyme with strand displacement capabilities and a minimum of four primers
recognizing six specific regions of a sequence as seen below in figure 2A and 2B. An additional
two primers, loop forward and loop back, can be added for increased specificity and reaction
efficiency. The use of reverse transcriptase allows this assay to be used for RNA applications
formally called RT-LAMP (19). In RT-LAMP reverse transcription of the RNA template into
copy DNA is performed before amplification occurs. The advantages of this methodology are
7

that it can be performed without the use of expensive thermocyclers, only requiring a heat source
that can provide a consistent output of 65°C. This isothermal capability is due to the strand
displacement activity of the Bst DNA polymerase enzyme. The last example of an advantage of
using LAMP is that the sample input can be purified nucleic acid or a crude sample lysate, which
enhances the turn-around time, usability, and affordability of the assay (19).
B

A

Figure 2 LAMP Primer Binding Schematics. (A)
Primer binding regions utilized by FIP, BIP, B3, F3,
Loop forward, and Loop back primers and their
relative locations within the target sequence. (B)
LAMP process from initiation through formation of
the starting dumbbell amplicon required for
amplification.

End-point analysis of LAMP amplification includes many different methods, including
colorimetric, turbidimetric, gel electrophoresis, and nucleic acid dyes (21). The colorimetric endpoint analysis evaluates the color change of an indicator dye called phenol red incorporated into
the master mix. The change from pink to yellow is the result of a pH shift from basic to acidic.
During amplification, Bst DNA polymerase releases a pyrophosphate and hydrogen ion from the
8

addition of a dNTP resulting in acidification, causing this color change as a result of the
subsequent pH shift (26).
Turbidimetric LAMPs principle measures the amount of formed magnesium
pyrophosphate byproducts produced during the amplification process when pyrophosphate and
magnesium ions react (27). The more amplicons generated, the more byproducts released,
increasing sample turbidity in the form of a white precipitate, which is measured utilizing a
turbidimeter. A LAMP reaction of approximately 60 minutes can result in the expansion of up to
109 amplicons of a targeted sequence. Samples used in LAMP reactions can be purified nucleic
acids or crude sample lysates and are not subject to the interference of common PCR inhibitors
such as heme found in blood (27).
The initial aim of this project was to optimize a diagnostic workflow for asymptomatic
SARS-CoV-2 surveillance using saliva samples and the CDC N1 RT-PCR assay to produce a
test for campus-wide surveillance with a rapid turn-around-time. Due to the poor performance of
the CDC N1 RT-PCR assay, an RT-LAMP design is successful in detecting three specific gene
targets for SARS-CoV-2 and used for mass surveillance.
Methods
CDC N1 RT-PCR Assay Design
Primer stocks used in RT-PCR assays purchased through Integrated DNA Technologies
(IDT), and adequately reconstituted to 100 µM in IDTE buffer at 8.0 pH from IDT and stored at
-20°C. Prior, RT-PCR complete primer sets for the CDC N1 assay made in a cold block to a
concentration of 2, 4, and 6 µM for the combined forward and reverse primers, and 1.25, 2, or
2.5 µM for the Taqman probe.
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Figure 3 CDC N1 Primer and Probe Alignment to SARS-CoV-2 Nucleocapsid Genomic Sequence.
CDC N1 RT-PCR forward and reverse primers shown in a red font, and Taqman probe shown in a blue
font. Primers and probe anneal to their respective regions shown in larger black font within the template
strands.

Components of an RT-PCR reaction consist of 18 µL of complete LightCycler® 480
RNA Master Hydrolysis Probes master mix and 2 µL of a nucleic acid sample while kept in a
cold block and gently mixed by pipetting in the wells of Light Cycler 480 multiwell plate and
covered using Light Cycler 480 sealing foil from Roche. RT-PCR analysis performed using a
Roche Light Cycler 96 using the following parameters, reverse transcription at 63°C for 180
seconds followed by denaturation at 95°C for 10 seconds, annealing 55°C for 10 seconds,
extension at 72°C for 10 seconds, for 40 cycles using the FAM detection channel. Figure 3
shows the primer alignment of the CDC N1 forward primer, reverse primer, and probe to the
SARS-CoV-2 nucleocapsid gene creating a 72 base pair product.
RT-LAMP Assay Design
LAMP primers purchased through Integrated DNA Technologies (IDT) and properly
reconstituted to 100 µM in sterile IDTE buffer at 8.0 pH from IDT and stored at -20°C. RTLAMP complete primer sets for nucleocapsid, envelope, and Orf1ab are made to a working
concentration using the amounts listed in Table 1 below.
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Table 1 LAMP Complete Primer Mix Specifications.

LAMP primer mixes
LAMP primer

Stock concentration

Working
concentration

Final concentration
(Per 25 µL Reaction)

FIP
BIP
F3
B3
LB

100 µM
100 µM
100 µM
100 µM
100 µM
100 µM

16 µM
16 µM
2 µM
2 µM
4 µM
4 µM

1.6 µM
1.6 µM
0.2 µM
0.2 µM
0.4 µM
0.4 µM

LF (not in envelope set)

Primer alignment to the targeted SARS-CoV-2 gene sequences can be seen below for
primer set Orf1ab, envelope, and nucleocapsid in figures 4, 5 and 6 respectively, along with the
primer sequences shown in table 2.

Figure 4 Orf1ab Primer Alignment to SARS-CoV-2 Genomic Sequence. RT-LAMP primers aligned
to SARS-CoV-2 Orf1ab gene sequence.

Figure 5 Envelope Primer Alignment to SARS-CoV-2 Genomic Sequence. RT-LAMP primers
aligned to SARS-CoV-2 envelope gene sequence.
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Figure 6 Nucleocapsid Primer Alignment to SARS-CoV-2 Genomic Sequence. RT-LAMP primers
aligned to SARS-CoV-2 nucleocapsid gene sequence.

Table 2 RT-LAMP Primer Sequences for Orf1ab, Envelope, and Nucleocapsid.

RT-LAMP Primer Sequences
Primer
FIP
BIP
F3
B3
LF
LB

Primer
FIP
BIP
F3
B3
LF
LB

Orf1ab
Sequence
AGAGCAGCAGAAGTGGCACttttAGGTGATTGTGAAGAAGAAGAG
TCAACCTGAAGAAGAGCAAGAAttttCTGATTGTCCTCACTGCC
TCCAGATGAGGATGAAGAAGA
AGTCTGAACAACTGGTGTAAG
CTCATATTGAGTTGATGGCTCA
ACAAACTGTTGGTCAACAAGAC
Envelope
Sequence

ACCACGAAAGCAAGAAAAAGAAGTAttttTTCGTTTCGGAAGAGACAG
TTGCTAGTTACACTAGCCATCCTTttttAGGTTTTACAAGACTCACGT
AGCTGATGAGTACGAACTT
TTCAGATTTTTAACACGAGAGT

None

GCGCTTCGATTGTGTGC

Nucleocapsid
Primer
FIP
BIP
F3
B3
LF
LB

Sequence

TCTGGCCCAGTTCCTAGGTAGTttttCCAGACGAATTCGTGGTGG
AGACGGCATCATATGGGTTGCAttttCGGGTGCCAATGTGATCT
TGGCTACTACCGAAGAGCT
TGCAGCATTGTTAGCAGGAT
GGACTGAGATCTTTCATTTTACCGT
ACTGAGGGAGCCTTGAATACA
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RT-LAMP Colorimetric End-Point Analysis
Components of a colorimetric RT-LAMP reaction can be found below in table 3 and
consist of 20 µL of the LAMP complete master mix and 5 µL of nucleic acid sample and gently
mixed by pipetting the mixture while in a cold block. Amplification of samples occurs by
incubation for 40 minutes in a 65°C water bath and reaction inactivation by a 5-minute
incubation in a 95°C water bath. Samples cooled at room temperature before color change
interpretation.
Table 3 Colorimetric RT-LAMP Complete Master Mix Components.

RT-LAMP complete master mix components (Per Reaction)
Component

Volume (µL)

NEB WarmStart Colorimetric LAMP 2X
Master Mix (DNA & RNA)
Complete primer mix
Sterile molecular grade H2O
Total volume

12.5
2.5
5.0
20.0

RT-LAMP Turbidimetric End-point Analysis
Components of a turbidimetric RT-LAMP reaction can be found below in table 4 and
consist of 20 µL of the LAMP complete master mix, and 5 µL of nucleic acid sample and gently
mixed by pipetting. Amplification is performed using an Eiken LA-500 Loopamp Turbidimeter
using the SARS pre-programmed setting of amplification at 62.5°C for 45 minutes, and
inactivation at 80°C for 5 minutes.
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Table 4 Turbidimetric RT-LAMP Complete Master Mix Components.

RT-LAMP complete master mix components (Per Reaction)
Component

Volume (µL)

NEB WarmStart LAMP kit (DNA &
RNA)
Complete primer mix
Sterile molecular grade H2O
Total volume

12.5
2.5
5.0
20.0

Enzyme Restriction Digest
Restriction Digest Design
Nucleic acids used in restriction digests were generated by first reverse transcription
using 2 µM final concentration of LAMP primer B3, followed by LAMP F3 and B3 primers at a
final concentration of 1 µM each and amplification using RT-PCR and the KAPA SYBR fast
one-step kit with 20 µL complete master mix and 5 µL of nucleic acid. The annealing
temperature used was 65°C with 40 total PCR cycles. Restriction enzymes Apol-HF, Hpal, and
Nde1, were purchased from New England BioLabs (NEB) and stored at -20°C. The enzymes
Apol-HF, Hpal, and Ndel, were used to digest the Orf1ab, envelope, and nucleocapsid RT-PCR
amplicons. Below in figure 7 is a schematic of the enzyme digest of each target region. The
components and volumes of the restriction digest reaction are listed below in table 5 and added
in sterile PCR tubes kept in a cold block, with the last component addition being the restriction
enzyme. Tubes were incubated for 1 hour at 37°C and inactivated at 80 or 95°C for 20 minutes.
Samples were analyzed using agarose gel electrophoresis.
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Table 5 Restriction Digest Reaction Components.

Restriction digest reaction components
Component

Volume (µL)

New England BioLabs Restriction enzyme
New England BioLabs SmartCut Buffer
Molecular grade H2O
Nucleic Acid
Total volume

1.0
5.0
34.0
10.0
50.0

Figure 7 Restriction Digest Design. Enzyme Binding and Cut Sequence Specifications for Ndel,
Hpal, and Apol-HF. Recognition sequence is shown in blue lettering, and cut sites are shown with red
vertical lines. The expected fragments and sizes are identified at the bottom of the figure.

Agarose Gel Electrophoresis
Agarose gel electrophoresis is used to visualize nucleic acids using an ethidium bromide
(EtBr) dye. Gels were produced by combining the appropriate amount of powdered agarose and
volume of 1XTBE buffer into an Erlenmeyer flask. The mixture was heated in a microwave until
the agarose has fully dissolved, followed by the addition of EtBr. The solution was left to cool
until warm to the touch before pouring into a gel casting tray. Samples were prepared by combining
15 µL of a nucleic acid sample with 3 µL of New England BioLabs (6X) no SDS purple loading
dye. Ladders were composed of 1 µL of the appropriate DNA ladder, 1 µL New England BioLabs
(6X) no SDS purple loading dye into 4 µL of molecular grade H2O. 15 µL of each sample, and 6
µL of the ladder were loaded into their respective wells. Using a Bio-Rad Powerpac basic power
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supply, gels were run at 100-120V in 1XTBE solution for approximately 1 hour to 30 minutes.
Gels were imaged using a Bio-Rad ChemiDoc using the UV Ethidium Bromide setting.
Samples
Donor Sample Collection
Under IRB approval the inclusion criteria for each donor are to not be experiencing any
COVID19 symptoms, and no eating or drinking for at least 30 minutes prior to sample
collection. Prior to collection each donor and medical professional must have the appropriate
PPE and clean hands using soap and water or alcohol-based hand sanitizer. With or without the
assistance of the medical professional, the donor will collect approximately one to two milliliters
of saliva into a uniquely identified screw-top sterile tube without touching the rim of the tube
with their hands avoiding contamination. With the tube in one hand and the cap in the other, the
donor with tightly screw the top on their collection tube and place it into a holding rack.
Saliva Treatment
Prior to sample collection a level two-biosafety cabinet, from now on referred to as a
hood, is designated for strict COVID19 testing use. After proper saliva collection as described
above, donned with the appropriate PPE the sample is placed in a previously disinfected hood. A
1/10 dilution of saliva with molecular grade water is produced in a PCR tube followed with the
addition of 13 µL of 20 mg/mL Proteinase K (PK) from Biovision. Tubes are incubated at 56°C
in a hot water bath for 15 minutes, and inactivation of proteinase K follows with a 10-minute
incubation in a 95°C water bath. This treated saliva is the sample material used for the following
molecular applications, and is stored at room temperature or stored in an Eppendorf tube in a 80°C freezer for later use.
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Contrived Samples
Contrived samples are produced by combining treated saliva from a donor who is
negative for SARS-CoV-2 infection, and viral genetic material. The viral genetic material used is
purified SARS-CoV-2 genomic RNA from ATCC (ATCC number: VR-1986D lot: 70040832).
Contrived samples are stored at -80°C.
Results
CDC N1 RT-PCR Results
Initially, the CDC N1 RT-PCR forward and reverse primers were validated for use as the
surveillance assay to reduce the overall cost and was the first commercially available diagnostic
assay for SARS-CoV-2. Using a Roche LightCycler 96 and a standard 200 nM final primer
concentration per reaction using the CDC-recommended annealing temperature of 55.0°C, an
experiment to assess the quality of testing utilizing only the primers to lower the overall cost of
testing by excluding the probe. Figure 8 below shows the amplification curves and melt curve
analysis of the experiment assessing the quality of the CDC N1 primers. The image on the left
shows the amplification curves generated using 200 copies of purified SARS-CoV-2 genomic
RNA (a), human genomic DNA (b), IDTE buffer for the no template control (c) and
the Staphylococcus Epidermidis bacterial DNA control (d). The image on the right shows the
melt curve analysis of the 200 copies of SARS-CoV-2 genomic RNA (a) and purified human
genomic DNA (b). From these images, the primers can efficiently amplify SARS-CoV-2
genomic RNA generating a single product indicated by the single peak in the melt curve
analysis, but non-specifically amplify human genomic DNA, resulting in false positives.
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Figure 8 Non-specific binding of CDC N1 RT-PCR Forward and Reverse Primer Using SYBR
Green 1. Amplification of SARS-CoV-2 genomic RNA and human genomic DNA using CDC N1 RTPCR forward and reverse primers with detection using SYBR Green 1.

To increase the assay specificity, the CDC N1 Taqman probe was incorporated to reduce
human genomic DNA interference using simulated saliva samples. First, the recommended CDC
N1 primers (500 nM) and Taqman probe (125 nM) with an annealing temperature of 55.0°C
were used as the assay parameters. Shown in figure 9 below are the amplification curves for the
positive control of 1,000 copies of SARS-CoV-2 genomic RNA (a), contrived sample containing
500 copies of SARS-CoV-2 genomic RNA (b), contrived sample containing 1,000 copies of
SARS-CoV-2 genomic RNA (c), contrived sample containing 200 copies of SARS-CoV-2
genomic RNA (d), and the no-template control containing sterile IDTE buffer (e). Curves a, b,
and c have Ct-values of 27.59, 34.15, and 33.97 respectively. Using the CDC recommendations,
the reaction efficiency and Ct-values are not close to the expected values when using saliva
samples. The reaction efficiency is visually assessed by looking at the shape of the amplification
curves with a sigmoidal shape indicating an optimal reaction efficiency, which is not readily
apparent in the data shown here. This poor reaction efficiency negatively impacts the detection
ability of the assay seen specifically in curves b and c. These curves were generated using 500
and 1,000 copies of purified SARS-CoV-2 genomic RNA, respectively, and should produce
separate amplification curves due to their difference in nucleic acid concentration. Curves b and
c do not display the expected separation by Ct-value difference of 3.3 based on their difference
in nucleic acid input, indicating poor reaction efficiency. Steps to improve reaction efficiency
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other than modifying the primer sequences include their final concentration, the reaction
annealing temperature, and reagents to improve DNA polymerase performance.

Figure 9 Poor Test Performance of CDC N1 RT-PCR Using CDC Recommended N1 Primer and
Probe Concentrations. Following samples (a) Positive control is 1,000 copies of SARS-CoV-2 gRNA,
(b) contrived sample of 500 copies gRNA, (c) contrived sample of 1,000 copies gRNA, (d) contrived
sample of 200 copies gRNA, (e) no template control of IDTE buffer analyzed using CDC recommended
N1 primer and probe concentrations. Recommended final concentration of 500 nM for each primer and
125 nM for probe. Amplification curve for Negative control of saliva from a SARS-CoV-2 negative at
absorbance threshold line.

The initial attempt to optimize the CDC N1 assay used different primer and probe
concentrations to remedy the poor reaction efficiency and poor detection capability produced
when using the CDC recommended concentrations. Primers tested at a final concentration of 100
nM, 200 nM, and 300 nM each, with a probe concentration at 200 nM and 250 nM producing six
unique groups. Figure 10 below shows the amplification curves generated testing the six
different groups utilizing the same input samples as in the initial experiment. The bolded curves
(if present) in each graph indicate samples belonging to each group. The primer and probe
concentrations tested were above and below the CDC recommended use, which, regardless of the
modification, no improvement to the performance of the assay occurred. This analysis was
determined using the same criteria using the shape of the amplification curve, and the Ct-values
produced for each sample type.
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Figure 10 Failed Optimization for CDC N1 RT-PCR Primer and Probe Concentrations. Following
concentrations tested using an annealing temperature of 55.0°C are (1) 2 µM primer, 2.0 µM probe, (2) 2
µM primer, 2.5 µM, (3) 4 µM primer, 2.0 µM probe, (4) 4 µM primer, 2.5 µM probe, (5) 6 µM primer,
2.0 µM, and (6) 6 µM primer, 2.5 µM probe. Samples analyzed include positive control 1,000 copies of
purified SARS-CoV-2 gRNA, contrived samples containing 1,000, 500, and 200 copies of SARS-CoV-2
gRNA, no template control of IDTE buffer, and a negative control of saliva from a SARS-CoV-2 negative
donor. Bolded lines indicate samples analyzed using the respective concentrations.

The first optimization attempt of primer and probe concentration modification had no
positive effect on the assay, leading to the second optimization attempt, which was the alteration
of the annealing temperature used in the RT-PCR cycles to enhance the efficiency of the primers.
The annealing temperature was tested at 55.0, 57.6, 59.0, 60.3, 61.7, 62.9, 63.9, and 64.6°C
using 200 nM of each primer and 200 nM of Taqman probe. The primer and probe
concentrations were used because they produced the best reaction efficiency based on a visual
analysis of the previous experiment in figure 10 and produce similar results to the CDC
recommended concentrations. The samples used in this second optimization are the same as the
initial experiment, which generated the graphs in figure 11 below. The change in annealing
temperature from 55.0°C had no positive effect on the reaction efficiency indicated by the shape
of the amplification curves and their associated Ct-values. As seen in the images below, the more
the annealing temperature is increased, the more the assay's performance is negatively impacted.
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The lack of improvement when modifying the annealing temperature indicates the necessity of a
third approach to optimize this assay further.

Figure 11 Failed Optimization of CDC N1 RT-PCR Primer and Probe Annealing Temperatures.
RT-PCR analysis using 4 µM primer, 2.0 µM probe amplification with annealing temperature 55.064.6°C. Bolded amplification lines indicate samples amplified for each respective annealing temperature.
Positive control is 1,000 copies of SARS-CoV-2 gRNA. Contrived samples containing 1,000, 500, and
200 copies of gRNA. No template control of IDTE buffer, and a negative control of saliva from a SARSCoV-2 negative donor.

As in the first and second optimization attempts changing two different assay
characteristics failed to improve the performance; the third and final attempt at optimizing the
assay was the addition of 1 µL per reaction of the LightCycler® 480 RNA Master Hydrolysis
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Probe kit enhancer. The manufacturer recommended the enhancer when targeted nucleic acid
sequences are high in G/C content. This approach is evaluated because the targeted sequence of
the CDC N1 primers has roughly 50% G/C content. The final concentrations for each primer are
200 nM and 200 nM of the Taqman probe with the CDC recommended annealing temperature of
55.0°C. Figure 12 below shows the graph generated when using these parameters in addition to
the enhancer reagent. Shown here are the amplification curves for the positive control of 1,000
copies of SARS-CoV-2 genomic RNA (a), contrived sample containing 500 copies of SARSCoV-2 genomic RNA (b), contrived sample containing 1,000 copies of SARS-CoV-2 genomic
RNA (c), contrived sample containing 200 copies of SARS-CoV-2 genomic RNA (d), and the
no-template control containing sterile IDTE buffer (e). Respectively, the Ct-values for curves a-d
are 27.73, 35.99, 35.25, and 39.39. The amplification curve shape and individual Ct-values
generated show no significant improvement compared to data shown in figures 9-11, even with
the addition of the reaction enhancer. The enhancer composition isn’t specified by the
manufacturer but suspected to be Betaine or DMSO which increase DNA polymerase efficiency
making amplification of G/C nucleic acid rich regions easier.
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Figure 12 Failed Optimization of CDC N1 RT-PCR With Enhancer Reagent. RT-PCR analysis using
4 µM primer, 2 µM probe with amplification annealing temperature at 55.0°C. Samples are (a) Positive
control is 1,000 copies of SARS-CoV-2 gRNA, (b) contrived sample of 500 copies gRNA, (c) contrived
sample of 1,000 copies gRNA, (d) contrived sample of 200 copies gRNA, (e) no template control of
IDTE buffer and negative control of saliva from a SARS-CoV-2 negative donor. Each sample
supplemented with 1 µL enhancer.

Collectively, analysis using a Roche Light Cycler 96 and the LightCycler® 480 RNA
Master Hydrolysis Probe kit this data shows that the CDC N1 RT-PCR assay cannot be further
optimized by the adjustment of primer or probe concentrations, annealing temperature, or the use
of a reaction enhancer when testing saliva samples. The assay cannot detect ≤ 200 copies of
SARS-CoV-2 gRNA in contrived samples, and samples containing 500-1,000 copies generate
Ct-values non-representative of their nucleic acid concentration differences. This evidence
suggests that the CDC N1 primers are not compatible with saliva samples containing human
genomic DNA, which amplify with poor reaction efficiency, negatively affecting the assay's
performance.
RT-LAMP Colorimetric Results
The failure of the CDC N1 RT-PCR assay in producing robust results using saliva
samples, and the failed attempts at optimization led to the investigation and development of an
alternative assay design using RT-LAMP and independently developed and studied RT-LAMP
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primers for Orf1ab by Lamb et al. (13), envelope by Yang et al. (30), and the nucleocapsid by
Zhang et al. (31). Each primer set had performance evaluation using purified SARS-CoV-2
genomic RNA along with the limit of detection that was determined using the colorimetric endpoint analysis. To determine the performance of the individual primer sets, each used different
testing amounts of SARS-CoV-2 genomic RNA, performed in triplicate ranging from 2.5 copies
per reaction to 200 copies per reaction. Figure 13 shows the colorimetric results for each primer
set, with a pink color indicating no amplification and yellow indicating amplification occurred.
Column 1 contains IDTE buffer as the no-template control, column 2 contains the negative
control of saliva from a negative SARS-CoV-2 donor, and column 3 has the positive control of
400 copies per reaction SARS-CoV-2 genomic RNA. The colorimetric results from this
experiment show that all three primer sets can successfully detect SARS-CoV-2 gRNA, the
envelope primer set offers the most significant sensitivity, and the lowest amount of genomic
RNA per reaction that was detected in each triplicate by all three primer sets was 50 copies per
reaction.

Figure 13 Colorimetric RT-LAMP of SARS-CoV-2 gRNA Limit of Detection. Colorimetric
interpretation after incubation for 40 minutes at 65.0°C and inactivated at 95.0°C for 5 minutes. Red font
indicating limit of detection. Samples include IDTE buffer for non-template control, saliva from SARSCoV-2 negative donor for negative control, 400 copies of SARS-CoV-2 gRNA as positive control, and
purified SARS-CoV-2 genomic RNA at concentrations from 2.5 copies – 200 copies reaction.
Photographed using cell phone camera.
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To confirm the previous colorimetric results and determine the reproducibility of the
primers, repeat colorimetric RT-LAMP analysis using a similar setup testing SARS-CoV-2
gRNA amounts from 2.5 copies per reaction to 100 copies per reaction. Figure 14 below shows
the repeat experiment which generated similar colorimetric results shown in figure 13. Columns
one through three contain the same control material as previously mentioned. Based on the
reproducibility of the RT-LAMP colorimetric end-point analysis, 50 copies per reaction can be
considered the limit of detection for this study as 100% of the samples (18/18) reliably generated
a robust positive color change while containing the lowest amount of genomic RNA.

Figure 14 Colorimetric RT-LAMP of SARS-CoV-2 gRNA Limit of Detection Confirmation.
Colorimetric interpretation after incubation for 40 minutes at 65.0°C and inactivated at 95.0°C for 5
minutes. Red font indicating limit of detection. Samples include IDTE buffer for non-template control,
saliva from SARS-CoV-2 negative donor for negative control, 400 copies of SARS-CoV-2 gRNA as
positive control, and purified SARS-CoV-2 genomic RNA at concentrations from 2.5 copies – 100 copies
reaction. Photographed using cell phone camera.

Knowing that colorimetric RT-LAMP can reliably detect 50 copies per reaction of
purified gRNA, can these primers be used to detect SARS-CoV-2 gRNA in saliva samples? If
present PCR inhibitors in saliva do not inhibit detection, it is speculated that using contrived
SARS-CoV-2 saliva samples will likely have a higher limit of detection as the matrix of the
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sample increases, so does the detection limit of an essay. To determine the reliability of the
LAMP primers for clinical samples, contrived samples are assayed and composed of SARSCoV-2 using treated saliva from a SARS-CoV-2 negative donor. The appropriate amount of
ATCC purified viral RNA to achieve samples generating 50 copies per reaction to 250 copies per
reaction. Figure 15 shows the first application of contrived samples using the colorimetric assay
yielding the results below. Column 1 contains IDTE buffer as the no-template control, column 2
is the negative control containing saliva from a negative SARS-CoV-2 donor, and column 3 is
the positive control with 200 copies per reaction SARS-CoV-2 genomic RNA. The results
obtained show that saliva can be successfully used for SARS-CoV-2 detection using RT-LAMP
despite the difficulties associated with using saliva in molecular techniques. As expected,
introducing saliva as the sample matrix did negatively impact the assay's sensitivity compared to
using purified SARS-CoV-2 genomic RNA, but by the order of magnitude expected.

Figure 15 Colorimetric RT-LAMP of SARS-CoV-2 Contrived Samples Limit of Detection.
Colorimetric interpretation after incubation for 40 minutes at 65.0°C and inactivated at 95.0°C for 5
minutes. Red font indicating limit of detection. Samples include IDTE buffer for non-template control,
saliva from SARS-CoV-2 negative donor for negative control, 200 copies of SARS-CoV-2 gRNA as
positive control, and contrived samples containing SARS-CoV-2 genomic RNA at concentrations from 50
copies – 250 copies reaction. Photographed using cell phone camera.
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To determine the reproducibility of the assay using saliva samples and to confirm the
previous colorimetric results, the second round of colorimetric RT-LAMP was performed, shown
in Figure 16 below. Columns one through three contain the same control material as previously
mentioned with IDTE buffer as the no-template control, saliva negative for SARS-CoV-2 as the
negative control, and 100 copies per reaction of gRNA as the positive control. Contrived samples
used produced reactions with 175 copies to 300 copies of gRNA and analyzed in triplicate for
each primer set. Similar to the first experiment using contrived samples, the assay's sensitivity
was slightly impacted by using a more complex sample. As seen in the previous RT-LAMP
assays, each primer set performs differently, with the envelope primer set having the best
sensitivity. Based on the reproducibility, 200 copies per reaction can be considered the limit of
detection for this study as 100% of the samples (18/18) generated a robust positive color change
for all three primer sets in all reactions.

Figure 16 Colorimetric RT-LAMP of SARS-CoV-2 Contrived Samples Limit of Detection
confirmation. Colorimetric interpretation after incubation for 40 minutes at 65.0°C and inactivated at
95.0°C for 5 minutes. Red font indicating limit of detection. Samples include IDTE buffer for nontemplate control, saliva from SARS-CoV-2 negative donor for negative control, 200 copies of SARSCoV-2 gRNA as positive control, and contrived samples containing SARS-CoV-2 genomic RNA at
concentrations from 50 copies – 250 copies reaction. Photographed using cell phone camera.
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Restriction Digest Results
Purified SARS-CoV-2 Genomic RNA
To confirm that the expected product was produced during the RT-LAMP reaction, a
restriction digest is performed using amplicons generated from RT-LAMP F3 and B3 primers
from Orf1ab, envelope, and nucleocapsid primer sets. An amplicon of known size was generated
using a reverse transcribed template from the B3 LAMP primer as the input material in an RTPCR reaction. Nucleic acid was amplified with RT-LAMP using B3 from each primer set at a
working stock concentration of 20 µM and processed using the standard incubation and
inactivation steps. Next, RT-LAMP samples were used in an RT-PCR assay with 20 µM F3 and
B3 primer mix and amplified using the standard PCR protocol with the annealing temperature at
65°C. Table 6 below contains Ct-values of amplified samples from the RT-PCR experiment
using the F3 and B3 LAMP primers. Below in figure 17 shows the RT-PCR amplification curves
for each amplicon and their respective melt curves. Visually, the amplification curves show an
efficient reaction with all Ct-values below 32, as seen in the top image. The bottom three images
in figure 17 show the melt curves that indicate sufficient primer specificity, with one prominent
peak indicating one product was produced, which was used in the restriction digest.

Table 6 RT-PCR Data of Amplified SARS-CoV-2 Genomic RNA. RT-PCR amplification using
Orf1ab, Envelope, and Nucleocapsid LAMP F3 and B3 Primers for purified SARS-CoV-2 genomic RNA.
Primer set curve label and produced Ct-value.

RT-PCR data of F3:B3 amplification of gRNA samples
Primer set
Orf1ab
Envelope
Nucleocapsid

Curve label
A
B
C
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Ct-value
26.21
31.40
26.33

Figure 17 RT-PCR Analysis of SARS-CoV-2 Genomic RNA. Top: RT-PCR amplification curves using
F3 and B3 from Orf1ab (C), envelope (B), and nucleocapsid (A) LAMP primer set. Bottom: Melt curve
analysis for nucleocapsid, envelope, and Orf1ab respectively.

The amplicons generated using RT-PCR were used in a restriction digest using the
respective enzymes Apo1-HF to digest Orf1ab amplicons, Hpal to digest envelope amplicons,
and Ndel nucleocapsid amplicons, each enzyme making one cut. Following digestion and
enzyme inactivation, pre-digest and post-digest samples were analyzed using a 3% agarose gel
electrophoresed at 100 volts for 1 hour, shown in figure 18 below.
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Figure 18 Restriction Digest Confirms Amplification of SARS-CoV-2 Purified Genomic RNA. Lane
1 contains NEB ultra-low range DNA ladder. Pre-digest product RT-PCR product, post-digest product is
RT-PCR product digested with respective enzyme. 3% agarose gel electrophoresis, run at 120 Volts.

The expected pre-digest band size using Orf1ab F3 and B3 primers is 289 base pairs, and
the expected post-digest products using Apol-HF is 104 base pairs and 185 base pairs in length,
which matched the banding pattern achieved for both Orf1ab pre and post digest samples shown
in figure 18. In the Orf1ab post-digest specifically was some residual pre-digest product
remaining with a band at 289 base pairs. The expected pre-digest product size using the envelope
F3 and B3 primers is 216 base pairs, and the expected post-digest product using Hpal result band
sizes of 160 base pairs and 56 base pairs, which match the banding pattern achieved. In the postdigest analysis, the 56 base pair fragments displayed poor resolution, which resulted in a faint
band. Lastly, using the nucleocapsid F3 and B3 primers, the expected pre-digest size is 217 base
pairs, and the post-digest with Ndel, the fragments would be 140 base pairs and 77 base pairs in
length. The banding pattern produced matched the expected results. Like the envelope post-
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digest sample, the nucleocapsid post-digest sample 77 base pair products displayed a more
inadequate resolution, resulting in a faint band. From the restriction digest results shown in table
5, figure 17, and figure 18, it was determined that the LAMP F3 and B3 primers were specific to
their intended regions based on the RT-PCR and restriction digest results. The RT-PCR analysis
using the two LAMP primers produced a single amplicon indicated by the single peak in the melt
curve analysis. Confirmation of the product size using a restriction digest produced the expected
fragment lengths, indicating the specificity of the primers.
Contrived Samples
Knowing the LAMP F3 and B3 primers are specific to their regions of the SARS-CoV-2
genome, a restriction digest experiment was performed using contrived samples to determine the
specificity of the primers in the presence of human genomic DNA. Reverse transcription was
performed first using LAMP B3 amplification, followed by amplified using F3 and B3 primers
from each primer pair in RT-PCR. Below in table 7 and figure 19 below contains the RT-PCR
data produced when using contrived samples analyzed in duplicate. The top graph in figure 18
shows the amplification curves for all three primers sets; using visual evaluation, the
nucleocapsid showed the best reaction efficiency, followed by Orf1ab, and the envelope showed
minimal to no amplification. The bottom three graphs in figure 19 show the melt curve analysis
for each primer set, with prevalent non-specific binding of primer characterized by the multiple
curves/bumps of the line.
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Table 7 RT-PCR Data of Amplified SARS-CoV-2 in Contrived Samples. RT-PCR amplification
using Orf1ab, Envelope, and Nucleocapsid LAMP F3 and B3 Primers for contrived samples. Primer set
curve label and produced Ct-value.

RT-PCR data of F3:B3 amplification of contrived samples
Primer set

Curve label

Ct-value

Orf1ab
Orf1ab
Envelope
Envelope
Nucleocapsid
Nucleocapsid

A
B
C
D
E
F

33.84
34.41
42.65
26.62
26.77

Figure 19 RT-PCR Analysis of Amplified SARS-CoV-2 Nucleic Acid from Contrived Samples. Top:
RT-PCR amplification curves using F3 and B3 from Orf1ab (A, B), envelope (C, D), and nucleocapsid
(E, F) LAMP primer sets. Bottom: Melt curve analysis for Orf1ab, envelope, and nucleocapsid
respectively.

The material produced in the RT-PCR reaction was used in the restriction digest using the
same respective enzymes for each primer set as in the previous experiment. Following digestion
and enzyme inactivation, pre-digest and post-digest samples were analyzed using a 3% agarose
gel electrophoresed at 100 volts for 1 hour, shown in figure 20 below.
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Figure 20 Restriction Digest of Amplified SARS-CoV-2 Nucleic Acid from Contrived Samples. Lane
1 contains NEB 1kb DNA ladder. Pre-digest product RT-PCR product, post-digest product is RT-PCR
product digested with respective enzyme. 3% agarose gel electrophoresis, run at 120 Volts.

The generated results from table 7, figure 19, and figure 20 show that when contrived
samples are used, there was significant interference of the human genomic DNA. Interference
from human genomic DNA was first identified in the RT-PCR data, specifically in the melt
curve analysis. In contrast to using purified SARS-CoV-2 gRNA, the contrived samples
produced curves with multiple peaks or curves, which indicate that multiple products are being
generated. The significant increase also saw this interference in the number of bands seen in the
gel lanes for primers Orf1ab and nucleocapsid resulting from digested human genomic DNA.
Using this experimental design, the envelope primer set yielded no detectable nucleic acid on the
agarose gel when used with contrived samples. These two observed influences of saliva would
inhibit any reliable restriction digest analysis, but using purified genomic RNA increased the
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confidence in the specificity of the primers despite the interference of the human genomic DNA
in contrived samples.
RT-LAMP Turbidimetric Results
Evidence showing that the colorimetric LAMP end-point analysis combined with the
three independent studied primer sets can reliably and specifically detect 200 copies of SARSCoV-2 genomic RNA in a contrived sample; next experiments were performed to evaluate how
the Turbidimetric LAMP end-point analysis performs for SARS-CoV-2 detection in saliva.
Figure 21 below shows the use of Orf1ab, envelope, and nucleocapsid primer sets for SARSCoV-2 gRNA detection of contrived saliva samples. Samples used in the turbidimetric assay
include a negative control consisting of saliva from a SARS-CoV-2 negative donor and a
positive control consisting of 400 copies per reaction of SARS-CoV-2 genomic RNA. Contrived
samples contained a range of SARS-CoV-2 gRNA producing 50 copies to 1000 copies per
reaction, assayed in triplicate. Using an Eiken LA-500 Real-time Turbidimeter and the preprogrammed SARS setting, amplification was performed for 45 minutes, and post-analysis using
a 2% agarose gel electrophoresed for 30 minutes 120 volts shown below in figure 21.
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Figure 21 Turbidimetric LAMP Detection of SARS-CoV-2 in Contrived Samples. Lane 1 contains
NEB 1kb DNA ladder, lane 2 contains negative control (SARS-CoV-2 negative saliva), and lane 3
contains the positive control (400 copies SARS-CoV-2 genomic RNA). Tubes photographed using cell
phone camera. 3% agarose gel electrophoresis, run at 120 Volts.

Amplification was determined by the presence of any characteristic ladder banding
pattern in the gel, and the limit of detection was characterized by the lowest amount of nucleic
acid, where all samples generated a positive result. Using this approach, the lowest SARS-CoV-2
genomic RNA in a contrived sample that was positive in all primer and triplicates using the
turbidimetric end-point analysis was approximately 750 copies per reaction. To assess the
reproducibility and confirm the previous results, another turbidimetric RT-LAMP using
contrived samples was performed on a range of contrived samples producing 200 to 750 copies
per reaction, as shown below in figure 22.
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Figure 22 Turbidimetric RT-LAMP Detection of SARS-CoV-2 in Contrived Samples Confirmation.
Lane 1 contains NEB 1kb DNA ladder, lane 2 contains negative control (SARS-CoV-2 negative saliva),
and lane 3 contains the positive control (400 copies SARS-CoV-2 genomic RNA). Tubes photographed
using cell phone camera. 3% agarose gel electrophoresis, run at 120 Volts.

Figure 21 and figure 22 confirm that 750 copies per reaction was the limit of detection for
using this end-point analysis. Again, determined by the presence of a ladder banding pattern in
each triplicate in each primer, 100% of samples (18/18) tested in triplicate show positive
amplification for reactions with 750 copies of SARS-CoV-2 genomic RNA. Compared to the
experimentally determined LOD of the colorimetric end-point analysis (200 copies per reaction),
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the turbidimetric analysis had a somewhat decreased analytical sensitivity at 750 copies per
reaction.
Surveillance Study
A surveillance study was conducted with IRB approval, testing 47 saliva samples from 47
donors who met the inclusion criteria. As a means of releasing intracellular SARS-CoV-2
genomic RNA and minimize RNA degradation via RNases (naturally occurring enzymes that
digest RNA), saliva samples were treated using proteinase K (PK) treatment, by incubating 100
µL of saliva and 13 µL of PK for 1 minute at 37°C followed by PK inactivation at 95°C for 5
minutes using a Thermomixer. Next, 5 µL of the treated saliva was then added to 20 µL of
complete RT-LAMP master mix and incubated in a 65°C water bath for 40 minutes followed by
inactivation at 95°C for 5 minutes. Color change interpretation was performed after samples have
cooled to room temperature after the inactivation step. Figure 23 below shows the colorimetric
results at 10-minute intervals from donors 1-27 using the nucleocapsid primer set. Below each
reaction tube is the result interpretation with (-) indicating no amplification or a negative result
and a red (+) for amplification or a positive result. A positive result was determined by
comparing the color change to the positive control and the robustness of the color change itself.
The no-template control used is a sterile IDTE buffer. The negative control is saliva from a
SARS-CoV-2 negative donor. The positive control is saliva from a positive SARS-CoV-2 donor,
and the release control is negative donor saliva spiked with inactivated SARS-CoV-2 viral
particles (ATCC number: VR-1986HK lot: 70036071). Out of 27 saliva donors, three were
determined to have a positive colorimetric color change indicating the presence of potential
SARS-CoV-2 genetic material.
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Figure 23 Donor Saliva Samples 001-027 Tested Using Colorimetric RT-LAMP for SARS-CoV-2
Nucleocapsid Gene. Donor saliva samples 001-027 treated using saliva treatment protocol and analyzed
using RT-LAMP. No template control is IDTE buffer, negative control is saliva from SARS-CoV-2
negative donor, positive control is saliva from a SARS-CoV-2 positive donor, and the (R.C.) treatment
control is inactivated SARS-CoV-2 viral particles spiked in saliva. Photographed using cell phone
camera.

Following the same protocol, saliva from donors 028-035 were tested using RT-LAMP
using the nucleocapsid, envelope, and Orf1ab primer sets. The colorimetric results are shown
below in figure 24, showing one out of eight donor samples generating a positive color change
indicating the potential presence of SARS-CoV-2 genetic material. Samples display some
moderate evaporation as images were taken after storage.
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Figure 24 Donor Saliva Samples 028-035 Tested using Colorimetric RT-LAMP for SARS-CoV-2
Orf1ab, Envelope, and Nucleocapsid Genes. Donor saliva samples 028-035 treated using saliva
treatment protocol and analyzed using RT-LAMP. No template control is IDTE buffer, negative control is
saliva from SARS-CoV-2 negative donor, positive control is saliva from a SARS-CoV-2 positive donor,
and the (R.C.) treatment control is inactivated SARS-CoV-2 viral particles spiked in saliva. Photographed
using cell phone camera.

Following the same protocol, saliva from donors 036-047 were tested using RT-LAMP
using the nucleocapsid, envelope, and Orf1ab primer sets. The colorimetric results are shown
below in figure 25, showing one out of 12 donor samples generating a positive color change
indicating the presence of potential SARS-CoV-2 genetic material. Samples display some
moderate evaporation as images were taken after storage. Out of the 47 donor-treated saliva
samples tested using the RT-LAMP assay, five generated a positive color change giving a
positive test rate of 10%. The conclusion of this study was that this methodology was
successfully used for asymptomatic SARS-CoV-2 detection in donor saliva samples, and that the
prevalence of asymptomatic SARS-CoV-2 is higher than what is being reported by the
University.
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Figure 25 Donor Saliva Samples 036-047 Tested using Colorimetric RT-LAMP for SARS-CoV-2
Orf1ab, Envelope, and Nucleocapsid Genes. Donor saliva samples 036-047 treated using saliva
treatment protocol and analyzed using RT-LAMP. No template control is IDTE buffer, negative control is
saliva from SARS-CoV-2 negative donor, positive control is saliva from a SARS-CoV-2 positive donor,
and the (R.C.) treatment control is inactivated SARS-CoV-2 viral particles spiked in saliva. Photographed
using cell phone camera.
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DISCUSSION
This study is the first attempt at a workflow designed explicitly for asymptomatic SARSCoV-2 monitoring using a less invasive saliva sample for analysis employing RT-LAMP for
screening a campus population. The cumulative results show that the colorimetric RT-LAMP
design offers a high throughput workflow while providing the analytical sensitivity and
specificity required of a molecular assay and highlights the shortcomings of the emergency
released CDC N1 RT-PCR assay SARS-CoV-2 testing using saliva samples. RT-PCR
optimization attempts yielded no improvements in the assay's performance with changes to
primer and probe concentration, annealing temperature, or the use of the PCR kit enhancer.
Overall, these findings parallel many of the scientific community's complaints of poor analytical
performance when using the CDC N1 RT-PCR assay for SARS-CoV-2 testing, as previously
mentioned. The gathered experimental evidence suggests that the design of the CDC N1 primers
and probe is not optimal for use with saliva samples and requires modifications to enhance the
assay's performance.
With the poor performance, the assay could detect higher concentrations of SARS-CoV-2
nucleic acid around 500 copies in contrived samples but failed to detect samples having a lower
concentration of 200 copies per reaction. The poor sensitivity of the assay can be attributed to the
poor performance of the primers and probe as the reactions occur with poor efficiency,
negatively affecting the detection capabilities of the assay. Again, the poor performance is
indicated by the shape of the amplification curves not being sigmoidal, and the Ct-values and
orientation of curves generated using different amounts of SARS-CoV-2 nucleic acid are not
representative of the difference in concentrations. Similar to the contrived samples, using
purified SARS-CoV-2 genomic RNA yielded results displaying poor reaction efficiencies despite
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the absence of saliva and the use of the kit enhancer. The limit of detection becomes negatively
impacted, but the detection limit narrows the inclusion of the population tested, as symptomatic
populations would likely have higher viral loads compared to asymptomatic populations, which
would potentially cause a drastic increase in false-negative results. Again, patient testing using
the CDC N1 RT-PCR assay had the majority of testing a patient population who were mainly
symptomatic to save testing resources. However, any asymptomatic, post-exposure testing or
individuals early in the infection stage could receive false-negative results due to the assays' poor
sensitivity.
Another consideration is that the CDC N1 primer sequences are complementary to
regions within the human genome when analyzed with NCBI BLAST (data not shown), which,
when used in an RT-PCR reaction with SYBR Green 1 detection, has shown prominent nonspecific binding of the primers seen in the melt curve analysis. The CDC's attempt to curb this
undesirable outcome was the addition of the Taqman probe, which would bind to its specific
region within the borders of the PCR primers to increase the specificity of the detection. The
evidence gathered in this study has shown the incorporation of the probe to allow only the
detection of SARS-CoV-2 nucleic acid. However, due to the inefficiency of the primers and the
non-specific amplification, the detection is negatively affected when using saliva samples.
In contrast to the CDC N1 analysis, the colorimetric RT-LAMP assay demonstrated
excellent utility for asymptomatic SARS-CoV-2 monitoring using saliva samples. Evidence
presented throughout this study has shown the RT-LAMP design to be the superior methodology
in sensitivity, specificity, and high throughput testing capabilities. The limit of detection for the
CDC N1 RT-PCR assay is approximately 500-1,000 copies of RNA in a contrived sample, while
RT-LAMP demonstrated a limit of detection at approximately 200 copies in a contrived sample.
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The CDC N1 assay requires incorporating a Taqman probe to decrease the amount of nonspecific amplification detection of human genomic DNA due to the poor design of the primers,
while the RT-LAMP primers show no non-specific amplification of human genomic DNA in a
LAMP reaction. These findings of colorimetric RT-LAMPs superiority to RT-PCR in sensitivity
show comparable results to previously published studies (30, 31), and the increase in the limit of
detection shown in this study using contrived samples can be found in previously published data
that also found saliva pre-treatment strategies enhancing RT-LAMPs performance (17).
The RT-LAMP design outperforms RT-PCR in terms of sensitivity and specificity, targeting
three distinct regions of the SARS-CoV-2 genome resulting in a high level of reproducibility at
200 copies per reaction (18/18) using contrived samples. In addition, there is not any presence of
non-specific amplification of the negative saliva controls from SARS-CoV-2 negative donors in
the colorimetric and turbidimetric RT-LAMP applications.
The confirmatory study supporting the assay's specificity is the restriction digest
performed for both non-contrived and contrived samples. The approach to generating the input
nucleic acid for the digest consisted of reverse transcription using the B3 primer only, followed
by F3 and B3 amplification using RT-PCR. The F3 and B3 primers are used in the RT-PCR
reaction because they flank the outer regions of the targeted sequence of the RT-LAMP primer
set, generating a single product of a known size, which is required for this restriction digest
experiment. A pre-digest and post-digest sample was analyzed using gel electrophoresis for each
primer set, with each showing the expected pre-digest band size and at least one expected postdigest band size with precise resolution. This suboptimal clarity is likely due to the difficulty of
resolving small DNA fragments using gel electrophoresis resulting in faint bands as seen for the
expected bands ≤ 100 base pairs. Achieving the expected pre-digest and post-digest nucleic acid
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sequence lengths indicates that the primers bind specifically to their designed region within the
SARS-CoV-2 genome using purified SARS-CoV-2 genomic RNA. When this same technique is
applied using contrived samples, the results indicated significant human genomic DNA
interference within the saliva matrix. Unlike the purified gRNA, the digest using contrived
samples shows many bands per lane within the gel, indicating that human genomic DNA was
also digested, inhibiting any analysis of primer specificity using this technique.
In addition to RT-LAMP superiority over RT-PCR in sensitivity and specificity, the high
throughput capabilities are also more ideal by taking advantage of two characteristics of a LAMP
assay. LAMP can be used for many different sample types, such as purified nucleic acids and
even crude nucleic acid extractants, making analysis more accessible, faster, and cheaper. In
contrast, the RT-PCR assays suggest using purified nucleic acid samples, which increases the
workload, turn-around time, and cost of a test. The second characteristic of LAMP allowing
more excellent high throughput capabilities is that sample restriction is not based on the number
of expensive thermocyclers as when using RT-PCR, but rather the space within hot water baths
or heat blocks. This capability can allow for a much higher sample processing volume than what
could be achieved using thermocyclers.
Turbidimetric RT-LAMP is assessed for two purposes; the first used as an additional
confirmatory assay utilizing all three RT-LAMP primer sets with input nucleic acid using
contrived samples, and to determine which LAMP end-point analysis offers better usability
colorimetric or turbidimetric. The real-time turbidimeter data output was inaccurate as samples
with visible precipitation were not consistently detected using the analyzer; instead, samples
were analyzed using agarose gel electrophoresis. Results from this confirmatory analysis indicate
the RT-LAMP primers are specific to SARS-CoV-2 nucleic acid, but the RT-LAMP end-point
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analysis change to turbidimetric detection negatively impacted the limit of detection. This
supports the utility of the RT-LAMP primer sets and that the colorimetric end-point analysis is
the superior end-point methodology.
The need for a rapid and straightforward molecular assay for SARS-CoV-2 detection for
use in a campus setting was in great need, and the utility of three already studied RT-LAMP
primer sets gave the ability to begin immediate surveillance in mid-September in the height of
the pandemic before optimization of the workflow could be performed. This screening
comprised testing 47 saliva samples from 47 donors, primarily nursing students and RAs
displaying no COVID19 symptoms using RT-LAMP, which can be seen in figures 22-25. From
the brief study of 47 donor saliva samples, five generated a positive color change utilizing the
nucleocapsid primer set, yielding a 10% positive test rate. In comparison to symptomatic
individual testing reported by NMU of 0.6%, Marquette county of 2.0% in mid-September (4),
and 10.0% for the state of Michigan in mid-September (4) under the assumption the majority are
symptomatic.
Despite the results showing the high prevalence of asymptomatic SARS-CoV-2 positive
carriers, the University chose to halt any further testing using this well-studied workflow
permanently. The shutdown of testing resulted from a shortage in supplies in the laboratory
where confirmatory testing was completed, in which 0/5 donors who tested positive using the
RT-LAMP workflow tested negative using a multiplexed RT-PCR assay. Unknown to University
administration is that a multiplexed assay causes significant loss in sensitivity for each target
tested for, which leads to higher rates of false-positive results. Unlike the RT-LAMP assay, with
each reaction specific to a unique target allowing the assay to uphold its sensitivity and
specificity, specificity can be another concern when using multiplexed assays. With the
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optimization of the workflow completed, it is possible that the prevalence of SARS-CoV-2 could
have been more accurately assessed if this workflow was employed for university surveillance
and not abruptly shut down.
RT-LAMPs usability is superior not only for campus surveillance, but this assay can have
many other additional positive impacts in the context of this pandemic and future pandemics.
Not only does LAMP sensitivity and specificity make this molecular technique ideal for SARSCoV-2 testing, but also the methods adaptability. This molecular technique can be easily
modified to detect different viral variants or strains, such as the variants of SARS-CoV-2 that
have emerged in different parts of the world, making testing difficult. This adaptability is also
important when considering future pandemics as this methodology offers more sensitivity,
specificity, and the inclusion of a broader range of sample types compared to the standard PCR
method commonly used. In the context of this pandemic, the control of this pandemic and the
number of resources and lives saved could have been significantly improved if a better-suited
molecular technique was employed for testing, such as LAMP.
This workflow is the first of its kind to utilize less invasive saliva samples in an RTLAMP assay to detect asymptomatic SARS-CoV-2 using saliva samples from a university
population. This study found that the colorimetric RT-LAMP design is more user-friendly and
has a faster turn-around time, and has superior analytical sensitivity and specificity over the CDC
N1 RT-PCR assay. With successful optimization of the RT-LAMP workflow, a small
surveillance study of primarily nursing students and RAs found a significantly higher SARSCoV-2 campus prevalence of 10% than the <1% reported by the University. Despite the evidence
gathered in this study supporting the SARS-CoV-2 diagnostic capability of RT-LAMP, and the
use of other well-known organizations utilizing this methodology, the campus surveillance
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testing was shut down allowing undiagnosed asymptomatic SARS-CoV-2 carriers to continue in
university activities.
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